Alopecia is the medical term for hair loss. Hair loss can happen naturally or as a result of a disease or the use of certain medications. Some common types of alopecia include
- Androgenic alopecia is common in both men and women. It is also referred to as male- or female-pattern hair loss.
- Alopecia areata- Alopecia areata is also known as patchy baldness. Bald patches can appear anywhere on the body, but the majority of people get a round or oval patch on the scalp.
- Traction alopecia is caused by putting stress on the hair by pulling or stretching it repeatedly
Market Dynamics
Market players are focused on product launches or approvals, which is expected to drive growth of the global alopecia treatment market over the forecast period. For instance, in September 2021, Dr. Reddy's Laboratories Limited announced the launch of Minoxidil topical solution USP 2% and 5% for the treatment of female pattern hair loss (FPHL). Dr. Reddy's will market its products as Mintop 2 percent and Mintop Eva 5 percent, respectively. The launch comes after the Central Drugs Standard Control Organization (CDSCO) in India approved the use of Minoxidil topical solution USP 2% and 5% for the treatment of FPHL for the first time.
Market players are focused on inorganic strategies such as acquisitions, partnerships, and agreements with other market players. This is expected to drive the market growth over the forecast period. For instance, in August 2017, Aclaris Therapeutics, Inc., a biopharmaceutical company based in the U.S. acquired Confluence Life Sciences, Inc., which expanded Aclaris’ inflammation and immunology pipeline with the addition of Confluence’s lead product candidates CDD-450, topical Janus kinase inhibitors, and IL2-inducible T-cell kinase inhibitor programs.
Moreover, market players are focused on research and development activities is expected to propel the growth of the global alopecia treatment market. For instance, in August 2021, Pfizer Inc., a multinational biopharmaceutical company announced positive top-line results from the Phase 2b/3 ALLEGRO trial, which evaluated oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease characterized by an immune attack on hair follicles that causes hair loss on the scalp and can also affect the face and body.
Key features of the study
- This report provides an in-depth analysis of global alopecia treatment market, provides market size (USD Mn), and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players.
- It profiles leading players in the global alopecia treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include Aclaris Therapeutics, Inc., Fagron, Follicum AB, Cipla Inc., Arcutis Biotherapeutics, Dr. Reddy’s Laboratories Ltd., Himalaya Wellness Company, Eli Lilly and Company, Concert Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
- The global alopecia treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global alopecia treatment market.
Market Segmentation
- By Drug Class
- Corticosteroids
- 5 AR Inhibitors
- Vasodilators
- Others
- By Disease Type
- Alopecia Areata
- Androgenic Alopecia
- Traction Alopecia
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Geography
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Stemson Therapeutics
- OliX Pharmaceuticals, Inc.
- Pfizer Inc.
- Aclaris Therapeutics, Inc.
- Fagron, Follicum AB
- Cipla Inc.
- Arcutis Biotherapeutics
- Reddy’s Laboratories Ltd.
- Himalaya Wellness Company
- Cosmo Pharmaceuticals N.V.
- Equillium, Inc.
- Eli Lilly and Company
- Concert PharmaceuticIals Inc.
- Teva Pharmaceutical Industries Ltd.
